Kuda Kankanamage Hansani Niroshika

Kuda Kankanamage Hansani Niroshika

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
KNKuda Kankanamage Hansani Niroshika
Kuda Kankanamage Hansani Niroshika
KWKosala Weerakoon
Kosala Weerakoon
Neelaka MolagodaNeelaka Molagoda
Neelaka Molagoda
KSK.W. Samarakoon
K.W. Samarakoon
HWHarshi Weerakoon
Harshi Weerakoon
RJR.G.P.T. Jayasooriya
R.G.P.T. Jayasooriya
Tumor necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL) is a TNF superfamily cytokine primarily acknowledged for its ability to selectively induce apoptosis in cancer cells. Beyond its antitumor effects, recent literature emphasizes the pleiotropic functions of TRAIL in physiological states and acute/chronic non-malignant diseases indicating its potential to be a breakthrough in diagnostics. This review explores the current understanding of the dynamic role of circulating soluble TRAIL (sTRAIL) and its potential as both a diagnostic and prognostic marker. Multiple in vitro, in vivo, and clinical studies in a wide range of neoplastic and non-neoplastic diseases including infectious diseases have been carried out to explore the potential role of sTRAIL in disease pathogenesis and as well as the possibilities of using it as a diagnostic and prognostic marker. The expression of sTRAIL seems to be context-dependent suggesting further research, particularly towards establishing disease-specific cutoff values. However, the lack of standardization in the serum sTRAIL estimation and the absence of reference intervals remain significant barriers to its clinical application. Addressing these challenges is essential for using circulating sTRAIL as an accurate diagnostic and prognostic marker in clinical practice.

7 April 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KNKuda Kankanamage Hansani Niroshika
Kuda Kankanamage Hansani Niroshika
HWHarshi Weerakoon
Harshi Weerakoon
NHNalaka Herath
Nalaka Herath
KWKosala Weerakoon
Kosala Weerakoon
PJPrasad Jayasooriya
Prasad Jayasooriya
Chronic kidney disease (CKD) is increasingly recognized as a global public health concern, impacting about 800 million people worldwide. Despite having different CKD etiologies, apoptosis, inflammation and fibrosis are the central mechanisms of pathogenesis. Tumor necrosis factor (TNF)- related apoptosis-inducing ligand (TRAIL) is a critical regulator of these mechanisms, suggesting a prominent role in pathogenesis and progression of CKD. Therefore, systematic mapping of the available evidence is pivotal in identifying the exact role of TRAIL and its receptors in CKD. The proposed scoping review will be conducted in line with Arksey and O’Malley’s methodological framework and the Joanna Briggs Institute (JBI) reviewer’s manual. Accordingly, the review will be guided by the five-stage approach, namely (1) identify the research question; (2) identify relevant studies; (3) select studies; (4) chart the data; and (5) collate, summarize, and report the results. Eligibility criteria and search strategies will be formulated based on population, concept, and context (PCC) strategy. Articles published up to January 2026 will be searched using electronic databases (PubMed/ MEDLINE, Science Direct, Scopus, CINAHL, EMBASE, Web of Science and Cochrane Library) and clinical trial registries (ClinicalTrials.gov and WHO ICTRP). Reference lists of relevant reviews retrieved from Google Scholar will also be screened for grey literature. A formal quality appraisal of the selected studies will be conducted using the mixed-method appraisal tool (MMAT version 2018). The reporting will be done following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for the Scoping Reviews checklist. The literature search is expected to commence in March 2026, followed by study selection and data extraction by April 2026. Data synthesis will be completed by June 2026. The review protocol is registered at Open Science Framework (OSF) under https://doi.org/10.17605/OSF.IO/AENBX .

17 June 2026 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
KNKuda Kankanamage Hansani Niroshika
Kuda Kankanamage Hansani Niroshika
HWHarshi Weerakoon
Harshi Weerakoon
NHNalaka Herath
Nalaka Herath
SPSujani Premathilake
Sujani Premathilake
PJPrasad Jayasooriya
Prasad Jayasooriya
KWKosala Weerakoon
Kosala Weerakoon
Chronic kidney disease of uncertain etiology (CKDu) is a progressive nephropathy histologically characterized by tubulointerstitial fibrosis with varying d

11 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KNKuda Kankanamage Hansani Niroshika
Kuda Kankanamage Hansani Niroshika
HWHarshi Weerakoon
Harshi Weerakoon
NHNalaka Herath
Nalaka Herath
KWKosala Weerakoon
Kosala Weerakoon
PJPrasad Jayasooriya
Prasad Jayasooriya
Background Chronic kidney disease (CKD) is increasingly recognized as a global public health concern, impacting about 700 million people worldwide. Due to the presence of both pro- and anti-apoptotic properties, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) can be a double-edged sword in the pathogenesis and progression of CKD. Systematic mapping of the available evidence is pivotal in identifying the exact role of TRAIL in CKD. Therefore, this protocol explains the methodological approach for a scoping review to map evidence regarding the role of TRAIL and its receptors in CKD. Methods The proposed scoping review will be conducted in line with Arksey and O’Malley’s methodological framework and the Joanna Briggs Institute (JBI) reviewer’s manual. Accordingly, the review will be guided by the five-stage approach, namely (1) identify the research question; (2) identify relevant studies; (3) select studies; (4) chart the data; and (5) collate, summarize, and report the results. Eligibility criteria and search strategy will be formulated based on population, concept, and context (PCC) strategy. Articles published up to July 2025 will be searched using electronic databases, PubMed/MEDLINE, Science Direct, Scopus, CINAHL, and Cochrane Library, while considering the Google Scholar reference lists of review articles as grey literature sources. A formal quality appraisal of the selected studies will be conducted using the mixed-method appraisal tool (MMAT version 2018). The reporting will be done following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for the Scoping Reviews checklist. The literature search is expected to commence after the protocol acceptance process, followed by study selection and data extraction by November 2025. Data synthesis will be completed by February 2026. Scoping review registration The review protocol is registered at Open Science Framework (OSF) under https://doi.org/10.17605/OSF.IO/AENBX.